US20010041691A1 - Water soluble prodrugs of azole compounds - Google Patents
Water soluble prodrugs of azole compounds Download PDFInfo
- Publication number
- US20010041691A1 US20010041691A1 US09/757,438 US75743801A US2001041691A1 US 20010041691 A1 US20010041691 A1 US 20010041691A1 US 75743801 A US75743801 A US 75743801A US 2001041691 A1 US2001041691 A1 US 2001041691A1
- Authority
- US
- United States
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- tertiary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 16
- 229940002612 prodrug Drugs 0.000 title claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 21
- 150000003851 azoles Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 29
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 21
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 19
- 150000003852 triazoles Chemical class 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- -1 methylpyrazolyl Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000001273 butane Substances 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 12
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 7
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 239000012312 sodium hydride Substances 0.000 claims description 6
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- XYUHPPVEDOOPDE-ZIAGYGMSSA-N (2R,5R)-2,5-diamino-2,5-bis(4-aminobutyl)hexanedioic acid Chemical class NCCCC[C@@](N)(CC[C@](N)(CCCCN)C(O)=O)C(O)=O XYUHPPVEDOOPDE-ZIAGYGMSSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 17
- 0 *OC(*)(C)OP(=O)(O)O Chemical compound *OC(*)(C)OP(=O)(O)O 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 229940006461 iodide ion Drugs 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- ZMBZPMVMLZIOPS-UHFFFAOYSA-M ditert-butyl phosphate;tetrabutylazanium Chemical compound CC(C)(C)OP([O-])(=O)OC(C)(C)C.CCCC[N+](CCCC)(CCCC)CCCC ZMBZPMVMLZIOPS-UHFFFAOYSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 238000010934 O-alkylation reaction Methods 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- PJGJQVRXEUVAFT-UHFFFAOYSA-N chloroiodomethane Chemical compound ClCI PJGJQVRXEUVAFT-UHFFFAOYSA-N 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- LNJAJHJFSKUCIR-UHFFFAOYSA-N ditert-butyl chloromethyl phosphate Chemical compound CC(C)(C)OP(=O)(OCCl)OC(C)(C)C LNJAJHJFSKUCIR-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- LTTJWQWAJGWWCX-UHFFFAOYSA-N CC(C)(C)C(C)(CN1C=NC=N1)C(C)(C)C Chemical compound CC(C)(C)C(C)(CN1C=NC=N1)C(C)(C)C LTTJWQWAJGWWCX-UHFFFAOYSA-N 0.000 description 2
- OPAHEYNNJWPQPX-XLEXHMCLSA-N C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F Chemical compound C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F OPAHEYNNJWPQPX-XLEXHMCLSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- OKIIEJOIXGHUKX-UHFFFAOYSA-L cadmium iodide Chemical compound [Cd+2].[I-].[I-] OKIIEJOIXGHUKX-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- YEWZQCDRZRYAEB-UHFFFAOYSA-N ditert-butyl hydrogen phosphate Chemical compound CC(C)(C)OP(O)(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-N 0.000 description 2
- RRJHOMPUEYYASJ-UHFFFAOYSA-N ditert-butyl hydrogen phosphite Chemical compound CC(C)(C)OP(O)OC(C)(C)C RRJHOMPUEYYASJ-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- WFUBYPSJBBQSOU-UHFFFAOYSA-M rubidium iodide Chemical compound [Rb+].[I-] WFUBYPSJBBQSOU-UHFFFAOYSA-M 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- LDCIZKLOEBJBEG-RLQAIQALSA-N C.C.C.C.C.C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O Chemical compound C.C.C.C.C.C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O LDCIZKLOEBJBEG-RLQAIQALSA-N 0.000 description 1
- BEDPTOODLYVRIH-KOIJCSPOSA-N C.C.C.C.C=C(C1=CC=CC=C1Cl)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.CC(C)(C)C(CN1C=CC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F.CC1=CC=C(C2=CSC([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)=N2)C=C1.C[C@@H](C1=CC=C(C2=CC=NN2C)C=C1)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.C[C@@H](C1=NC=CC=C1F)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.[H]C(F)(F)C(F)(F)COC1=CC=C(/C=C/C2=NN(CC(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C=N2)C=C1.[H]C(F)(F)C(F)(F)COC1=CC=C(N2C=NN([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C2=O)C=C1 Chemical compound C.C.C.C.C=C(C1=CC=CC=C1Cl)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.CC(C)(C)C(CN1C=CC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F.CC1=CC=C(C2=CSC([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)=N2)C=C1.C[C@@H](C1=CC=C(C2=CC=NN2C)C=C1)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.C[C@@H](C1=NC=CC=C1F)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.[H]C(F)(F)C(F)(F)COC1=CC=C(/C=C/C2=NN(CC(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C=N2)C=C1.[H]C(F)(F)C(F)(F)COC1=CC=C(N2C=NN([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C2=O)C=C1 BEDPTOODLYVRIH-KOIJCSPOSA-N 0.000 description 1
- CYDAASIIMDTVQK-ASSLBZAWSA-N C.C=C(C1=CC=CC=C1Cl)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.CC(C)(C)C(CN1C=CC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F.CC1=CC=C(C2=CSC([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)=N2)C=C1.C[C@@H](C1=CC=C(C2=CC=NN2C)C=C1)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.C[C@@H](C1=NC=CC=C1F)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.[H]C(C)(F)C(F)(F)COC1=CC=C(/C=C/C2=NN(CC(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C=N2)C=C1 Chemical compound C.C=C(C1=CC=CC=C1Cl)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.CC(C)(C)C(CN1C=CC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F.CC1=CC=C(C2=CSC([C@H](C)C(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)=N2)C=C1.C[C@@H](C1=CC=C(C2=CC=NN2C)C=C1)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.C[C@@H](C1=NC=CC=C1F)C(CN1C=NC=N1)(C1=CC=C(F)C=C1F)C(C)(C)C.[H]C(C)(F)C(F)(F)COC1=CC=C(/C=C/C2=NN(CC(CN3C=NC=N3)(C3=CC=C(F)C=C3F)C(C)(C)C)C=N2)C=C1 CYDAASIIMDTVQK-ASSLBZAWSA-N 0.000 description 1
- YWASBZMHELPXCO-IAGBLQLVSA-N C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O Chemical compound C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC(C)(C)C(CN1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O)C(C)(C)C.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)C5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5COC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O.CC[C@@H]([C@H](C)C(C)(C)C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@H]5OCC(CN6C=NC=N6)(C6=CC=C(F)C=C6F)O5)C=C4)CC3)C=C2)C1=O YWASBZMHELPXCO-IAGBLQLVSA-N 0.000 description 1
- XMIMHGNAHYUWNV-UHFFFAOYSA-N C.CC(C)(C)OP(=O)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)OC(C)(C)C Chemical compound C.CC(C)(C)OP(=O)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)OC(C)(C)C XMIMHGNAHYUWNV-UHFFFAOYSA-N 0.000 description 1
- AIZCYLFWMHQEDB-UMKVHLARSA-N CC(=O)NC(C)[C@@H](C)C(=O)OC1CC2(O)C(OC(=O)C3=CC=CC=C3)C3[C@]4(O[Ac])COC4CC(C)(C)[C@@]3(C)C(C)(C)[C@H](C)C(=C1C)C2(C)C Chemical compound CC(=O)NC(C)[C@@H](C)C(=O)OC1CC2(O)C(OC(=O)C3=CC=CC=C3)C3[C@]4(O[Ac])COC4CC(C)(C)[C@@]3(C)C(C)(C)[C@H](C)C(=C1C)C2(C)C AIZCYLFWMHQEDB-UMKVHLARSA-N 0.000 description 1
- YJPSQWWPTNVFRF-BWCBJYAWSA-M CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O)O)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F.II.[V]I Chemical compound CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O)O)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F.II.[V]I YJPSQWWPTNVFRF-BWCBJYAWSA-M 0.000 description 1
- GBSOMSAHMWHIOU-DSACSDBWSA-M CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F.II.[V]I Chemical compound CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(O)(CN1C=NC=N1)C1=CC=C(F)C=C1F.II.[V]I GBSOMSAHMWHIOU-DSACSDBWSA-M 0.000 description 1
- RNKQHSLJQJTZDC-WGCWVIOISA-N CC1=CC(C[N+]2=CN(CC(O)(C3=CC=C(F)C=C3F)[C@@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3)N=C2)=CC(C)=C1OC(=O)C1CCCN1 Chemical compound CC1=CC(C[N+]2=CN(CC(O)(C3=CC=C(F)C=C3F)[C@@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3)N=C2)=CC(C)=C1OC(=O)C1CCCN1 RNKQHSLJQJTZDC-WGCWVIOISA-N 0.000 description 1
- UNCIGNCWLSQBMQ-AQQIIWQUSA-N CCOC(=O)OC(C(=O)OC1CC2(O)[C@@H](C)C3[C@]4(O[Ac])COC4CC(OCOP(=O)(O)O)[C@@]3(C)C(=O)C(O[Ac])C(=C1C)C2(C)C)C(NC(=O)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CCOC(=O)OC(C(=O)OC1CC2(O)[C@@H](C)C3[C@]4(O[Ac])COC4CC(OCOP(=O)(O)O)[C@@]3(C)C(=O)C(O[Ac])C(=C1C)C2(C)C)C(NC(=O)C1=CC=CC=C1)C1=CC=CC=C1 UNCIGNCWLSQBMQ-AQQIIWQUSA-N 0.000 description 1
- DURYPOBJYWREKK-PAFVTKIRSA-N CC[C@@H]([C@H](C)OC(=O)CN)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@@H]5CO[C@@](CN6C=NC=N6)(C6=C(F)C=C(F)C=C6)C5)C=C4)CC3)C=C2)C1=O Chemical compound CC[C@@H]([C@H](C)OC(=O)CN)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@@H]5CO[C@@](CN6C=NC=N6)(C6=C(F)C=C(F)C=C6)C5)C=C4)CC3)C=C2)C1=O DURYPOBJYWREKK-PAFVTKIRSA-N 0.000 description 1
- DSJAEJLNCRDEFE-YGYSHTTHSA-K C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F.[V]I Chemical compound C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)C1=CC=C(F)C=C1F.C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F.[V]I DSJAEJLNCRDEFE-YGYSHTTHSA-K 0.000 description 1
- MXTIJBUSJYCGSN-HTLIEODRSA-L C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F Chemical compound C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OCOP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F MXTIJBUSJYCGSN-HTLIEODRSA-L 0.000 description 1
- WXINNFXEPNDEPJ-UTTGIEMOSA-L C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F Chemical compound C[C@@H](C1=NC(C2=CC=C(C#N)C=C2)=CS1)C(CN1C=NC=N1)(OP(=O)(O[Na])O[Na])C1=CC=C(F)C=C1F WXINNFXEPNDEPJ-UTTGIEMOSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- SGUXGJPBTNFBAD-UHFFFAOYSA-L barium iodide Chemical compound [I-].[I-].[Ba+2] SGUXGJPBTNFBAD-UHFFFAOYSA-L 0.000 description 1
- 229910001638 barium iodide Inorganic materials 0.000 description 1
- 229940075444 barium iodide Drugs 0.000 description 1
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940075417 cadmium iodide Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AVWLPUQJODERGA-UHFFFAOYSA-L cobalt(2+);diiodide Chemical compound [Co+2].[I-].[I-] AVWLPUQJODERGA-UHFFFAOYSA-L 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LNGNZSMIUVQZOX-UHFFFAOYSA-L disodium;dioxido(sulfanylidene)-$l^{4}-sulfane Chemical compound [Na+].[Na+].[O-]S([O-])=S LNGNZSMIUVQZOX-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- VBKBIDUVUIYPEC-UHFFFAOYSA-N phosphonooxymethoxymethyl dihydrogen phosphate Chemical compound OP(O)(=O)OCOCOP(O)(O)=O VBKBIDUVUIYPEC-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- CBTMHLJHDJNTMB-UHFFFAOYSA-M silver;ditert-butyl phosphate Chemical compound [Ag+].CC(C)(C)OP([O-])(=O)OC(C)(C)C CBTMHLJHDJNTMB-UHFFFAOYSA-M 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- This invention relates to novel water-soluble azole compounds useful for the treatment of serious systemic fungal infections and suitable for both oral and, particularly, parenteral administration. More particularly, the invention relates to novel water-soluble prodrugs having the general formula:
- A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group
- R and R 1 are each independently hydrogen or (C 1 -C 6 )alkyl, or pharmaceutically acceptable salts thereof.
- Triazole antifungal compounds are well known in the prior art. Of the several classes known, one particularly potent class contains a tertiary hydroxyl group.
- one particularly potent class contains a tertiary hydroxyl group.
- U.S. Pat. No. 5,648,372 discloses that (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol has anti-fungal activity.
- WO 97/28169 discloses that a phosphate moiety can be attached directly to the tertiary hydroxyl portion of the anti-fungal compound, e.g. the compound having the formula
- X is OP(O)(OH) 2 or an easily hydrolyzable ester OC(O)RNR 1 R 2 .
- WO 95/17407 discloses water-soluble azole prodrugs of the general formula
- X is P(O)(OH) 2 , C(O)—(CHR 1 ) n —OP(O)(OH) 2 or C(O)—(CHR 1 ) n —(OCHR 1 CHR 1 ) m OR 2 .
- WO 96/38443 discloses water-soluble azole prodrugs of the general formula
- U.S. Pat. No. 5,883,097 discloses water-soluble amino acid azole prodrugs such as the glycine ester
- European Patent Application 604910 discloses phosphonooxymethyl taxane derivatives of the general formula
- R 1 , R 2′′ , R 3′ , R 6′ or R 7′ is OCH 2 OP(O)(OH) 2 .
- European Patent Application 639577 discloses phosphonooxymethyl taxane derivatives of the formula T-[OCH 2 (OCH 2 ) m OP(O)(OH) 2 ] n wherein T is a taxane moiety bearing on the C13 carbon atom a substituted 3-amino-2-hydroxypropanoyloxy group; n is 1, 2 or 3; m is 0 or an integer from 1 to 6 inclusive, and pharmaceutically acceptable salts thereof.
- WO 99/38873 discloses O-phosphonooxymethyl ether prodrugs of a diaryl 1,3,4-oxadiazolone potassium channel opener.
- triazole anti-fungal compounds containing a secondary or tertiary hydroxyl group including (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-butan-2-ol, may be converted into prodrugs with superior properties to those previously disclosed by attaching a phosphate containing moiety via a linking group.
- the invention covers compounds of the formula:
- A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group
- R and R 1 are each independently hydrogen or (C 1 -C 6 )alkyl, or pharmaceutically acceptable salts thereof.
- the compounds of general formula I function as “prodrugs” when administered in vivo, being converted to the biologically active parent azole in the presence of alkaline phosphatase.
- A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary hydroxy group.
- A can be any organic compound having the following properties:
- R 3 represents phenyl substituted by one or more (preferably 1-3) halogen atoms
- R 4 represents H or CH 3 ;
- R 5 represents H, or taken together with R 4 may represent ⁇ CH 2 ;
- R 6 represents a 5- or 6 membered nitrogen containing ring which may be optionally substituted by one or more groups selected from halogen, ⁇ O, phenyl substituted by one or more groups selected from CN, (C 6 H 4 )—OCH 2 CF 2 CHF 2 and CH ⁇ CH—(C 6 H 4 )—OCH 2 CF 2 CHF 2 , or phenyl substituted by one or more groups selected from halogen and methylpyrazolyl.
- Nitrogen containing heterocycles which R 6 may represent include triazolyl, pyrimidinyl, and thiazolyl.
- (C 1 -C 6 )alkyl refers to a straight or branched chain saturated aliphatic group having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, etc.
- pharmaceutically acceptable salt as used herein is intended to include phosphate salts with such counterions as ammonium, metal salts, salts with amino acids, salts with amines and salts with other bases such as piperidine or morpholine. Both mono- and bis-salts are intended to be encompassed by the term “pharmaceutically acceptable salts”.
- Specific embodiments include ammonium, sodium, calcium, magnesium, cesium, lithium, potassium, barium, zinc, aluminum, lysine, arginine, histidine, methylamine, ethylamine, t-butylamine, cyclohexylamine, N-methylglucamine, ethylenediamine, glycine, procaine, benzathene, diethanolamine, triethanolamine, piperidine and morpholine.
- halogen as used herein includes chloro, bromo, fluoro and iodo, and is preferably chloro or fluoro, and most preferably fluoro.
- the compounds of the present invention can be solvated or non-solvated.
- a preferred solvate is a hydrate.
- a most preferred embodiment of the present invention is (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-[(dihydrogen phosphonoxy)methoxy]butane or a pharmaceutically acceptable salt thereof.
- This prodrug exhibits much improved aqueous solubility (>10 mg/mL at pH 7, 5-6 mg/mL at pH 4.3) compared with the parent compound which enables it to be used for parenteral administration as well as oral administration.
- This compound is also stable in solution, can be isolated in crystalline form and is readily converted to parent drug in vivo.
- A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary or secondary hydroxyl group
- Pr represents a conventional hydroxy-protecting groups such as t-butyl, benzyl or allyl
- R and R 1 are each independently hydrogen or (C 1 -C 6 )alkyl. Most preferably, R and R 1 are both hydrogen.
- the antifungal parent compound of interest, II is converted into the phosphate intermediate IV by O-alkylation with chloride intermediate III in the presence of a suitable base such as sodium hydride, potassium hydride, sodium amide, sodium t-butoxide, potassium t-butoxide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or combinations thereof such as sodium hydride plus sodium bis(trimethylsilyl)amide.
- a suitable base such as sodium hydride, potassium hydride, sodium amide, sodium t-butoxide, potassium t-butoxide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or combinations thereof such as sodium hydride plus sodium bis(trimethylsilyl)amide.
- This reaction step may be carried out in an inert organic solvent such as tetrahydrofuran, methyl-tetrahydrofuran, methyl t-butyl ether, diethylether or dimethylacetamide at a temperature of from about 0° to 50° C., more preferably between about 20° to 40° C., and most preferably at about 40° C.
- the most preferred base is sodium hydride and the most preferred solvent is tetrahydrofuran.
- the most preferred R and R 1 groups are hydrogen.
- Ester intermediate IV is then subjected to a conventional deprotection step to remove the hydroxyl-protecting groups Pr.
- the reagents used in such step will depend on the particular hydroxyl-protecting group used, but will be well known to those skilled in the art.
- the most preferred hydroxy protecting group is the t-butyl group which can be removed with trifluoroacetic acid, hydrochloric acid or formic acid in an appropriate inert organic solvent.
- the inert solvent may be, for example, methylene chloride, dichloroethane, methylbenzene or trifluoromethyl benzene.
- the deprotection step in trifluoroacetic acid in methylene chloride at a temperature of from about 0° to 40° C., most preferably at a temperature of about 0-5° C.
- the final product I may then be recovered and purified by conventional procedures such as reverse phase C-18 column chromatography or solvent extraction.
- End product I may, of course, be converted by conventional means to a desired pharmaceutically acceptable salt as described above.
- the source of iodide ion is preferably sodium iodide, but may also include lithium iodide, cesium iodide, cadmium iodide, cobalt iodide, copper iodide, rubidium iodide, barium iodide, zinc iodide and calcium iodide.
- About 2-3 equivalents of the iodide salt is generally used per equivalent of parent compound A—OH.
- the pharmaceutically active compounds of this invention may be used alone or formulated as pharmaceutical compositions comprising, in addition to the active triazole ingredient, a pharmaceutically acceptable carrier, adjuvant or diluent.
- the compounds may be administered by a variety of means, for example, orally, topically or parenterally (intravenous or intramuscular injection).
- the pharmaceutical compositions may be in solid form such as capsules, tablets, powders, etc. or in liquid form such as solutions, suspensions or emulsions.
- Compositions for injection may be prepared in unit dose form in ampules or in multidose containers and may contain additives such as suspending, stabilizing and dispersing agents.
- the compositions may be in ready-to-use form or in powder form for reconstitution at the time of delivery with a suitable vehicle such as sterile water.
- the compounds of the present invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, or cream. Additionally, they may be incorporated (at a concentration up to 10%) into an ointment consisting of a white wax or soft, white paraffin base together with the required stabilizers and/or preservatives.
- the compounds of the invention are useful because they possess pharmacological activities in animals, including particularly mammals and most particularly, humans.
- the compounds of the present invention are useful for the treatment or prevention of topical fungal infections, including those caused by species of Candida, Trichophyton, Microsporum, or Epidermophyton.
- they are useful for the treatment of mucosal infections caused by Candida albicans. They can also be used in the treatment of systemic fungal infections caused, for example, by species of Candida albicans, Cryptococcus neoformans, Aspergillus flavus, Aspergillus fumigatus, Coccidioides, Paracoccidiodes, Histoplasma, or Blastomyces.
- a method of treating a fungal infection which comprises administering a therapeutically effective amount of the compound to a host, particularly a mammalian host and most particularly a human patient.
- a host particularly a mammalian host and most particularly a human patient.
- the use of the compounds of the present invention as pharmaceuticals and the use of the compounds of the invention in the manufacture of a medicament for the treatment of fungal infections are also provided.
- the dosage to be administered depends, to a large extent, on the particular compound being used, the particular composition formulated, the route of administration, the nature and condition of the host and the particular situs and organism being treated. Selection of the particular preferred dosage and route of application, then, is left to the discretion of the physician or veterinarian. In general, however, the compounds may be administered parenterally or orally to mammalian hosts in an amount of from about 5 mg/day to about 1.0 g/day. These doses are exemplary of the average case, and there can be individual instances where higher or lower dosages are merited, and such dosages are within the scope of this invention. Furthermore, administration of the compounds of the present inventions can be conducted in either single or divided doses.
- the in vitro evaluation of the antifungal activities of the compounds of the invention can be performed by determining the minimum inhibitory concentration (MIC).
- MIC is the concentration of test compound which inhibits the growth of the test microorganism.
- a series of agar plates, each having the test compound incorporated at a specific concentration is inoculated with a fungal strain and each plate is then incubated for 48 h at 37° C. The plates are examined for the presence or absence of fungal growth, and the relevant concentration is noted.
- Microorganisms which can be used in the test include Candida albicans, Asperigillus fumigatus, Trichophyton spp., Microsporum spp., Epidermophyton floccosum, Coccidioides immitis, and Torulopsos galbrata. It should be recognized that, as prodrugs, some compounds of the invention may not be active in the in vitro test.
- the in vivo evaluation of compounds of the present invention can be carried out at a series of dose levels by intraperitoneal or intravenous injection or by oral administration to mice which have been inoculated with a strain of fungus (e.g. Candida albicans ). Activity is determined by comparing the survival of the treated group of mice at different dosage levels after the death of an untreated group of mice. The dose level at which the test compound provides 50% protection against the lethal effect of the infection is noted.
- a strain of fungus e.g. Candida albicans
- the compounds of the present invention substantially increase the solubility of the parent triazole antifungal compound and also release the bioactive parent compound (i.e. function as a prodrug) as demonstrated in human liver S9 experiments.
- Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; dd, doublet of doublets; dt, doublet of triplets; and app d, apparent doublet, etc.
- Mass spectra were recorded on a Kratos MS-50 or a Finnegan 4500 instrument utilizing direct chemical ionization (DCI, isobutene), fast atom bombardment (FAB), or electron ion spray (ESI).
- DCI direct chemical ionization
- FAB fast atom bombardment
- ESI electron ion spray
- Analytical thin-layer chromatography was carried out on precoated silica gel plates (60F-254) and visualized using UV light, iodine vapors, and/or staining by heating with methanolic phosphomolybdic acid.
- Reverse phase chromatography was performed in a glass column using C18 silica gel (Waters Corporation Preparative C18 125A) at pressures somewhat above atmospheric pressure.
- the pH of the aqueous layer was adjusted to 7.6 by addition of solid Na 2 CO 3 and then the organic and aqueous layers were separated.
- the aqueous layer was then subjected to reverse phase chromatography on 400 g of C-18 eluted with H 2 O to 5% CH 3 CN/H 2 O.
- the product containing fractions were concentrated under reduced pressure, frozen and lyophilized to afford 1.5 g of the subtitled compound, I, as a white solid. (1.5 g, 12% over two steps).
- Di-tert-butyl chloromethyl phosphate, III may be made by any of the following methods.
- Tetrabutylammonium di-t-butyl phosphate was prepared by dissolving di-t-butyl phosphate [20 g, 94 mmol (obtained from di-t-butyl phosphite by the method of Zwierzak and Kluba, Tetrahedron, 1971, 27, 3163)] in methanolic tetrabutylammonium hydroxide (47 mL of 1M solution, 47 mmol). The reaction mixture had a temperature of 23° C. and pH of 4.33.
- the pH of the reaction mixture was adjusted to 6.5-7.0 by addition of methanolic tetrabutylammonium hydroxide (48 mL of 1M solution, 48 mmol) over 0.2 h.
- the reaction mixture was stirred for 0.5 h at approximately 26° C. and then was concentrated under reduced pressure at a bath temperature below 40° C.
- the crude residue was azeotroped three times by adding toluene (3 ⁇ 100 mL) and then the mixture was concentrated under reduced pressure.
- the crude residue was then triturated in cold hexanes (0° C.) for 1 h and then the solid was collected by filtration, washed with a minimum amount of cold hexanes and dried to give a first crop of tetrabutylammonium di-t-butyl phosphate as a white solid. (24.0 g).
- the mother liquor was concentrated under reduced pressure and then triturated in cold hexanes (20 mL) for 1 h.
- the solid was collected by filtration, washed with a minimum amount of cold hexanes and dried to give a second crop of tetrabutylammonium di-t-butyl phosphate as a white solid. [(8.5 g), 32.5 g total (77%)].
- Iodochloromethane (974 g, 402 mL, 5.53 mol) at 25° C. was treated with tetrabutylammonium di-t-butylphosphate (250 g, 0.553 mol). The phosphate was added portionwise over 10 minutes. The heterogeneous mixture became a clear pink solution after approximately 15 minutes. The mixture was stirred for three hours, and the iodochloromethane was then removed by rotary evaporation with a bath temperature of ⁇ 30° C. The residue was taken up in 1 L t-butyl methyl ether and stirred for 15 minutes to precipitate tetrabutylammonium iodide by-product. Tetrabutylammonium iodide was removed by vacuum filtration through a sintered glass funnel. The filtrate was concentrated by rotary evaporation to an oil which contained a 5:1 mixture of III and undesired dimer impurity
- the mixture can be purified by a silica gel chromatography to obtain III as pure compound in ⁇ 60% yield as an oil.
- the aqueous layer containing the title product as bis sodium salt was treated with activated charcoal (10 g) and filtered through a bed of Celite.
- the clear filtrate was acidified with IN HCl to pH 2.5.
- the free acid, the title product was extracted into ethyl acetate (2 ⁇ 50 mL).
- the combined organic layer was washed with water, dried over MgSO 4 , filtered, and the filtrate concentrated under reduced pressure to afford 3.39 g of crude title product.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymerization Catalysts (AREA)
Abstract
Description
-
- wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group, R and R1 are each independently hydrogen or (C1-C6)alkyl, or pharmaceutically acceptable salts thereof.
- Triazole antifungal compounds are well known in the prior art. Of the several classes known, one particularly potent class contains a tertiary hydroxyl group. For example, U.S. Pat. No. 5,648,372 discloses that (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol has anti-fungal activity.
- The utility of this class of compounds is limited by their low water solubility. For example, the solubility of the above triazole compound in water at pH 6.8 is 0.0006 mg/mL. This greatly impedes developing suitable parenteral dosage forms.
-
-
-
- wherein X is OP(O)(OH)2 or an easily hydrolyzable ester OC(O)RNR1R2.
-
- wherein X is P(O)(OH)2, C(O)—(CHR1)n—OP(O)(OH)2 or C(O)—(CHR1)n —(OCHR1CHR1)mOR2.
-
-
- The introduction of the phosphonooxymethyl moiety into hydroxyl containing drugs has been disclosed as a method to prepare water-soluble prodrugs of hydroxyl containing drugs.
-
- wherein at least one of R1, R2″, R3′, R6′ or R7′ is OCH2OP(O)(OH)2.
- European Patent Application 639577 discloses phosphonooxymethyl taxane derivatives of the formula T-[OCH2(OCH2)mOP(O)(OH)2]n wherein T is a taxane moiety bearing on the C13 carbon atom a substituted 3-amino-2-hydroxypropanoyloxy group; n is 1, 2 or 3; m is 0 or an integer from 1 to 6 inclusive, and pharmaceutically acceptable salts thereof.
- WO 99/38873 discloses O-phosphonooxymethyl ether prodrugs of a diaryl 1,3,4-oxadiazolone potassium channel opener.
-
- It has now been found that triazole anti-fungal compounds containing a secondary or tertiary hydroxyl group, including (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-butan-2-ol, may be converted into prodrugs with superior properties to those previously disclosed by attaching a phosphate containing moiety via a linking group. Specifically, the invention covers compounds of the formula:
- wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group, R and R1 are each independently hydrogen or (C1-C6)alkyl, or pharmaceutically acceptable salts thereof.
- The compounds of general formula I function as “prodrugs” when administered in vivo, being converted to the biologically active parent azole in the presence of alkaline phosphatase.
- Preferred among the compounds of formula I are those wherein R and R1 are both hydrogen.
- In a preferred embodiment, A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary hydroxy group.
-
- wherein R3 represents phenyl substituted by one or more (preferably 1-3) halogen atoms;
- R4 represents H or CH3;
- R5 represents H, or taken together with R4 may represent ═CH2;
- R6 represents a 5- or 6 membered nitrogen containing ring which may be optionally substituted by one or more groups selected from halogen, ═O, phenyl substituted by one or more groups selected from CN, (C6H4)—OCH2CF2CHF2 and CH═CH—(C6H4)—OCH2CF2CHF2, or phenyl substituted by one or more groups selected from halogen and methylpyrazolyl.
- Nitrogen containing heterocycles which R6 may represent include triazolyl, pyrimidinyl, and thiazolyl.
-
- In addition to the application of the present invention to structures containing a tertiary alcohol, it should also be understood that this discovery can be applied to anti-fungal agents which contain secondary alcohols. Some examples of the non-hydroxy portion of triazole antifungal compounds of the type containing a secondary hydroxy group include, but are not limited to, the following:
- As used herein “(C1-C6)alkyl” refers to a straight or branched chain saturated aliphatic group having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, etc.
- The term “pharmaceutically acceptable salt” as used herein is intended to include phosphate salts with such counterions as ammonium, metal salts, salts with amino acids, salts with amines and salts with other bases such as piperidine or morpholine. Both mono- and bis-salts are intended to be encompassed by the term “pharmaceutically acceptable salts”. Specific embodiments include ammonium, sodium, calcium, magnesium, cesium, lithium, potassium, barium, zinc, aluminum, lysine, arginine, histidine, methylamine, ethylamine, t-butylamine, cyclohexylamine, N-methylglucamine, ethylenediamine, glycine, procaine, benzathene, diethanolamine, triethanolamine, piperidine and morpholine. For the most preferred embodiment, (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-[(dihydrogen phosphonoxy)methoxy]butane, the t-butylamine and lysine salts are especially preferred as they can be obtained as single polymorph crystalline solids of high purity with good solubility and stability.
- The term “halogen” as used herein includes chloro, bromo, fluoro and iodo, and is preferably chloro or fluoro, and most preferably fluoro.
- The compounds of the present invention can be solvated or non-solvated. A preferred solvate is a hydrate.
- A most preferred embodiment of the present invention is (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-[(dihydrogen phosphonoxy)methoxy]butane or a pharmaceutically acceptable salt thereof. This prodrug exhibits much improved aqueous solubility (>10 mg/mL at pH 7, 5-6 mg/mL at pH 4.3) compared with the parent compound which enables it to be used for parenteral administration as well as oral administration. This compound is also stable in solution, can be isolated in crystalline form and is readily converted to parent drug in vivo.
- The compounds of the present invention may be made by the following general reaction scheme. In this method, A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary or secondary hydroxyl group, Pr represents a conventional hydroxy-protecting groups such as t-butyl, benzyl or allyl, and R and R1 are each independently hydrogen or (C1-C6)alkyl. Most preferably, R and R1 are both hydrogen.
- To elaborate on the method, the antifungal parent compound of interest, II, is converted into the phosphate intermediate IV by O-alkylation with chloride intermediate III in the presence of a suitable base such as sodium hydride, potassium hydride, sodium amide, sodium t-butoxide, potassium t-butoxide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or combinations thereof such as sodium hydride plus sodium bis(trimethylsilyl)amide. This reaction step may be carried out in an inert organic solvent such as tetrahydrofuran, methyl-tetrahydrofuran, methyl t-butyl ether, diethylether or dimethylacetamide at a temperature of from about 0° to 50° C., more preferably between about 20° to 40° C., and most preferably at about 40° C. The most preferred base is sodium hydride and the most preferred solvent is tetrahydrofuran. The most preferred R and R1 groups are hydrogen.
- Ester intermediate IV is then subjected to a conventional deprotection step to remove the hydroxyl-protecting groups Pr. The reagents used in such step will depend on the particular hydroxyl-protecting group used, but will be well known to those skilled in the art. The most preferred hydroxy protecting group is the t-butyl group which can be removed with trifluoroacetic acid, hydrochloric acid or formic acid in an appropriate inert organic solvent. The inert solvent may be, for example, methylene chloride, dichloroethane, methylbenzene or trifluoromethyl benzene. In the case of the preferred deprotection step with the di-tertiary butyl ester, it is preferred to do the deprotection step in trifluoroacetic acid in methylene chloride at a temperature of from about 0° to 40° C., most preferably at a temperature of about 0-5° C.
- The final product I may then be recovered and purified by conventional procedures such as reverse phase C-18 column chromatography or solvent extraction.
- End product I may, of course, be converted by conventional means to a desired pharmaceutically acceptable salt as described above.
- It was later discovered that use of purified reagent III gave fairly low yields of intermediate IV (approximately 10-35% yield) in the above reaction, resulting in low overall yields of product I. However, when a source of iodide ion is added to the O-alkylation step of the above reaction, the yield of intermediate IV is unexpectedly increased to up to about 90%, thus also significantly increasing the yield of final product I. It is believed that the addition of the iodide ion may result in in situ formation of the corresponding iodide intermediate III′ of the formula
- and that use of this reagent results in a large increase in yield of the phosphate intermediate IV. The attempt to substitute preformed intermediate III′ directly for intermediate III in the first step of the above reaction, however, was unsuccessful due to the greatly decreased stability of iodide reagent III′ compared to the chloride intermediate III. An alternative method which was successful involves using iodine in the O-alkylation step along with chloride intermediate III in the presence of base such as NaH (which also may act as a reducing agent for the iodine). It is believed that the iodine is reduced to iodide ion which then converts chloride intermediate III in situ to iodide intermediate III′ to facilitate this step of the process. The illustrative example below shows the O-alkylation step using elemental iodine which is the preferred method of carrying out this reaction to get intermediate IV.
- By forming the iodide reagent III′ in situ by addition of a source of iodide ion or by reaction of iodine and reagent III in the presence of strong base, the greatly increased yield of phosphate ester IV allows the final product I to be also obtained in greatly increased yield.
- The source of iodide ion is preferably sodium iodide, but may also include lithium iodide, cesium iodide, cadmium iodide, cobalt iodide, copper iodide, rubidium iodide, barium iodide, zinc iodide and calcium iodide. About 2-3 equivalents of the iodide salt is generally used per equivalent of parent compound A—OH.
- When elemental iodine is used in the coupling step, about 0.1 to 1.0 equivalent of iodine, preferably 0.5 equivalent, is employed per equivalent of parent compound A—OH.
- The bases and solvents which are used when iodine or iodide ion is used are the same as those described above when reagent III is used per se.
- It will be understood that where the substituent groups used in the above reactions contain certain reaction sensitive functional groups such as amino or carboxylate groups which might result in undesirable side-reactions, such groups may be protected by conventional protecting groups known to those skilled in the art. Suitable protecting groups and methods for their removal are illustrated, for example, inProtective Groups in Organic Synthesis, Theodora W. Greene (John Wiley & Sons, 1991). It is intended that such “protected” intermediates and end-products are included within the scope of the present disclosure and claims.
- It will be appreciated that certain products within the scope of formula I may have substituent groups which can result in formation of optical isomers. It is intended that the present invention include within its scope all such optical isomers as well as epimeric mixtures thereof, i.e. R— or S— or racemic forms.
- The pharmaceutically active compounds of this invention may be used alone or formulated as pharmaceutical compositions comprising, in addition to the active triazole ingredient, a pharmaceutically acceptable carrier, adjuvant or diluent. The compounds may be administered by a variety of means, for example, orally, topically or parenterally (intravenous or intramuscular injection). The pharmaceutical compositions may be in solid form such as capsules, tablets, powders, etc. or in liquid form such as solutions, suspensions or emulsions. Compositions for injection may be prepared in unit dose form in ampules or in multidose containers and may contain additives such as suspending, stabilizing and dispersing agents. The compositions may be in ready-to-use form or in powder form for reconstitution at the time of delivery with a suitable vehicle such as sterile water.
- Alternatively, the compounds of the present invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, or cream. Additionally, they may be incorporated (at a concentration up to 10%) into an ointment consisting of a white wax or soft, white paraffin base together with the required stabilizers and/or preservatives.
- The compounds of the invention are useful because they possess pharmacological activities in animals, including particularly mammals and most particularly, humans. Specifically, the compounds of the present invention are useful for the treatment or prevention of topical fungal infections, including those caused by species of Candida, Trichophyton, Microsporum, or Epidermophyton. Additionally, they are useful for the treatment of mucosal infections caused byCandida albicans. They can also be used in the treatment of systemic fungal infections caused, for example, by species of Candida albicans, Cryptococcus neoformans, Aspergillus flavus, Aspergillus fumigatus, Coccidioides, Paracoccidiodes, Histoplasma, or Blastomyces.
- Thus, according to another aspect of the invention, there is provided a method of treating a fungal infection which comprises administering a therapeutically effective amount of the compound to a host, particularly a mammalian host and most particularly a human patient. The use of the compounds of the present invention as pharmaceuticals and the use of the compounds of the invention in the manufacture of a medicament for the treatment of fungal infections are also provided.
- The dosage to be administered depends, to a large extent, on the particular compound being used, the particular composition formulated, the route of administration, the nature and condition of the host and the particular situs and organism being treated. Selection of the particular preferred dosage and route of application, then, is left to the discretion of the physician or veterinarian. In general, however, the compounds may be administered parenterally or orally to mammalian hosts in an amount of from about 5 mg/day to about 1.0 g/day. These doses are exemplary of the average case, and there can be individual instances where higher or lower dosages are merited, and such dosages are within the scope of this invention. Furthermore, administration of the compounds of the present inventions can be conducted in either single or divided doses.
- The in vitro evaluation of the antifungal activities of the compounds of the invention can be performed by determining the minimum inhibitory concentration (MIC). The MIC is the concentration of test compound which inhibits the growth of the test microorganism. In practice, a series of agar plates, each having the test compound incorporated at a specific concentration, is inoculated with a fungal strain and each plate is then incubated for 48 h at 37° C. The plates are examined for the presence or absence of fungal growth, and the relevant concentration is noted. Microorganisms which can be used in the test includeCandida albicans, Asperigillus fumigatus, Trichophyton spp., Microsporum spp., Epidermophyton floccosum, Coccidioides immitis, and Torulopsos galbrata. It should be recognized that, as prodrugs, some compounds of the invention may not be active in the in vitro test.
- The in vivo evaluation of compounds of the present invention can be carried out at a series of dose levels by intraperitoneal or intravenous injection or by oral administration to mice which have been inoculated with a strain of fungus (e.g.Candida albicans). Activity is determined by comparing the survival of the treated group of mice at different dosage levels after the death of an untreated group of mice. The dose level at which the test compound provides 50% protection against the lethal effect of the infection is noted.
- The compounds of the present invention substantially increase the solubility of the parent triazole antifungal compound and also release the bioactive parent compound (i.e. function as a prodrug) as demonstrated in human liver S9 experiments.
- The following examples illustrate the invention, but are not intended as a limitation thereof. The abbreviations used in the examples are conventional abbreviations well-known to those skilled in the art. Some of the abbreviations used are as follows:
h = hour(s) rt = room temperature mmol = mmole(s) g = gram(s) THF = tetrahydrofuran mL = milliliter(s) L = liter(s) Et2O = diethyl ether EtOAc = ethyl acetate TFA = trifluoroacetic acid CH2Cl2 = dichloromethane CH3CN = acetonitrile - In the following examples, all temperatures are given in degrees Centigrade. Melting points were determined on an electrothermal apparatus and are not corrected. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker −500, Bruker AM-300 or a Varian Gemini 300 spectrometer. All spectra were determined in CDCl3 or D2O unless otherwise indicated. Chemical shifts are reported in δ units (ppm) relative to tetramethylsilane (TMS) or a reference solvent peak and interproton coupling constants are reported in Hertz (Hz). Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; dd, doublet of doublets; dt, doublet of triplets; and app d, apparent doublet, etc. Mass spectra were recorded on a Kratos MS-50 or a Finnegan 4500 instrument utilizing direct chemical ionization (DCI, isobutene), fast atom bombardment (FAB), or electron ion spray (ESI).
- Analytical thin-layer chromatography (TLC) was carried out on precoated silica gel plates (60F-254) and visualized using UV light, iodine vapors, and/or staining by heating with methanolic phosphomolybdic acid. Reverse phase chromatography was performed in a glass column using C18 silica gel (Waters Corporation Preparative C18 125A) at pressures somewhat above atmospheric pressure.
-
-
- To a solution of (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, II, (8.74 g, 20 mmol) in THF (40 mL) under a nitrogen atmosphere was added sodium hydride (0.80 g, 60% in oil, 20 mmol) at rt. The resulting mixture was stirred at rt for 0.25 h and then di-tert-butyl chloromethyl phosphate, III (10.3 g, 40 mmol) was added. The reaction mixture was heated at 50° C. for 16 h. The reaction mixture was then allowed to cool to rt and was concentrated under reduced pressure. The residue was dissolved in Et2O and was washed with H2O and brine. The organic layer was dried over MgSO4 and was concentrated under reduced pressure to obtain 17.0 g of crude subtitled compound, IV, as a gum. A small portion of this crude compound was purified by reverse phase chromatography on C-18. The column was eluted with 30% CH3CN/H2O, 38% CH3CN/H2O, 45% CH3CN/H2O and then 50% CH3CN/H2O. The product containing fractions were concentrated under reduced pressure in order to remove CH3CN. The resulting aqueous layer was then extracted with Et2O. The Et2O layers were washed with brine, dried and concentrated under reduced pressure to afford purified subtitled compound, IV, as a white solid.
-
-
- The crude (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-[(di-tert-butyl phosphonoxy)methoxy]butane, IV, (17 g) was dissolved in CH2Cl2 (100 mL). To this solution was added TFA (50 mL) and the reaction mixture was stirred at rt for 0.25 h. The reaction mixture was then concentrated under reduced pressure. To the residue was added H2O (200 mL), Et2O (100 mL) and EtOAc (100 mL). The pH of the aqueous layer was adjusted to 7.6 by addition of solid Na2CO3 and then the organic and aqueous layers were separated. The aqueous layer was then subjected to reverse phase chromatography on 400 g of C-18 eluted with H2O to 5% CH3CN/H2O. The product containing fractions were concentrated under reduced pressure, frozen and lyophilized to afford 1.5 g of the subtitled compound, I, as a white solid. (1.5 g, 12% over two steps).
-
- Di-tert-butyl chloromethyl phosphate, III, may be made by any of the following methods.
- Silver di-t-butyl phosphate (6.34 g, 20 mmol), which was prepared by mixing di-t-butyl phosphate (obtained from di-t-butyl phosphite by the method of Zwierzak and Kluba, Tetrahedron, 1971, 27, 3163) with one equivalent of silver carbonate in 50% aqueous acetonitrile and by lyophilizing to dryness, was placed together with chloroiodomethane (35 g, 200 mmol) in benzene and stirred at room temperature for 18 hrs. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. The residue was chromatographed on silica and eluted with 2:1 hexanes-ethyl acetate. Appropriate fractions were concentrated to dryness to obtain the subtitled compound III (3.7 g, 71% yield):
-
- Tetrabutylammonium di-t-butyl phosphate was prepared by dissolving di-t-butyl phosphate [20 g, 94 mmol (obtained from di-t-butyl phosphite by the method of Zwierzak and Kluba, Tetrahedron, 1971, 27, 3163)] in methanolic tetrabutylammonium hydroxide (47 mL of 1M solution, 47 mmol). The reaction mixture had a temperature of 23° C. and pH of 4.33. The pH of the reaction mixture was adjusted to 6.5-7.0 by addition of methanolic tetrabutylammonium hydroxide (48 mL of 1M solution, 48 mmol) over 0.2 h. The reaction mixture was stirred for 0.5 h at approximately 26° C. and then was concentrated under reduced pressure at a bath temperature below 40° C. The crude residue was azeotroped three times by adding toluene (3×100 mL) and then the mixture was concentrated under reduced pressure. The crude residue was then triturated in cold hexanes (0° C.) for 1 h and then the solid was collected by filtration, washed with a minimum amount of cold hexanes and dried to give a first crop of tetrabutylammonium di-t-butyl phosphate as a white solid. (24.0 g). The mother liquor was concentrated under reduced pressure and then triturated in cold hexanes (20 mL) for 1 h. The solid was collected by filtration, washed with a minimum amount of cold hexanes and dried to give a second crop of tetrabutylammonium di-t-butyl phosphate as a white solid. [(8.5 g), 32.5 g total (77%)]. A solution of tetrabutylammonium di-t-butyl phosphate (218 g, 480 mmol) in benzene (200 mL) was added dropwise to stirred chloroiodomethane (800 g, 4535 mmol) over 1.5 h at rt. The reaction mixture was stirred an additional 1.5 h at rt and then was concentrated under reduced pressure. The oily residue was dissolved in Et2O and filtered to remove white solids which had precipitated. The organic layer was washed with saturated NaHCO3 and H2O/brine (1/1). The organic layer was then dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield a red brown oil (320 g). The red brown oil was subjected to chromatography on silica gel (800 g) eluted with 20% EtOAc/Hexanes, 25% EtOAc/Hexanes then 30% EtOAc/Hexanes. The product containing fractions were concentrated under reduced pressure to yield a golden oil. The oil was diluted with CH2Cl2 (30 mL), concentrated under reduced pressure and then dried under vacuum to yield the subtitled compound III (61.3 g, 49% yield). 1IIH NMR (Benzene-d6) δ5.20 (2H, d, J=15), 1.22 (18H, s).
- Iodochloromethane (974 g, 402 mL, 5.53 mol) at 25° C. was treated with tetrabutylammonium di-t-butylphosphate (250 g, 0.553 mol). The phosphate was added portionwise over 10 minutes. The heterogeneous mixture became a clear pink solution after approximately 15 minutes. The mixture was stirred for three hours, and the iodochloromethane was then removed by rotary evaporation with a bath temperature of <30° C. The residue was taken up in 1 L t-butyl methyl ether and stirred for 15 minutes to precipitate tetrabutylammonium iodide by-product. Tetrabutylammonium iodide was removed by vacuum filtration through a sintered glass funnel. The filtrate was concentrated by rotary evaporation to an oil which contained a 5:1 mixture of III and undesired dimer impurity
- The mixture can be purified by a silica gel chromatography to obtain III as pure compound in ˜60% yield as an oil.
-
- A. An oven dried, IL round-bottom flask equipped with a mechanical stirrer, nitrogen inlet adapter, pressure-equalizing addition funnel fitted with a rubber septum and temperature probe was charged with sodium hydride (2.89 g, 0.069 mol, 60%) and THF (50 mL). To this stirred suspension, (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)butan-2-ol, II, (10 g, 0.023 mol) in 30 mL of THF was added dropwise over 20 minutes at room temperature. After stirring for 45 minutes, a solution of iodine (2.99 g, 0.0115 mol) in THF (30 mL)) was added dropwise over 10 minutes followed by dropwise addition of compound di tert butylchloromethyl phosphate, III (13.29 g, 0.035 mol, ˜68% purity) over 15 minutes. The reaction mixture was stirred for 4 hours at about 41° C. to complete the reaction. The completion of the reaction was judged by in-process HPLC. The reaction mixture was poured into ice cold water (100 mL). The aqueous phase was separated and extracted with ethyl acetate (3×50 mL) and the combined organic extract was washed with 10% sodium thiosulfite (50 mL), water (50 mL), brine (50 mL), dried over magnesium sulfate and concentrated under reduced pressure to give pale yellow oil (22.8 g, In-process HPLC: ˜97% pure). The crude product was used “as is” in step B.
- B. To a round-bottom flask equipped with magnetic stirrer, cooling bath, pH probe and N2 inlet-outlet was charged the product of Step A above (7.5 g) in CH2Cl2 (23 mL) and cooled to 0° C. To this stirred solution, trifluoroacetic acid (8.8 mL) was added slowly and stirred for 3 h to complete the reaction. The completion of the reaction was judged by in-process HPLC. The reaction mixture was poured into a cold solution of 2N NaOH (64 mL). The reaction mixture was extracted with t-butyl acetate (2×65 mL) to remove all the organic impurities. The aqueous layer containing the title product as bis sodium salt was treated with activated charcoal (10 g) and filtered through a bed of Celite. The clear filtrate was acidified with IN HCl to pH 2.5. The free acid, the title product, was extracted into ethyl acetate (2×50 mL). The combined organic layer was washed with water, dried over MgSO4, filtered, and the filtrate concentrated under reduced pressure to afford 3.39 g of crude title product.
- The above obtained title product from Example 2 was dissolved in methanol (75 mL) and to this L-lysine (1.8 g) was added and heated at 60° C. for 4.5 h. The hot reaction mixture was filtered through a bed of Celite. The filtrate was concentrated to about 5 mL, mixed with ethanol (100 mL) and heated to 65° C. to crystallize the bis lysine salt. The salt was collected on a Buchner funnel and dried under vacuum to afford 3.71 g of the title compound as an off white crystalline solid.
- A solution of title product of Example 2 was dissolved in 50 mL of ethyl acetate and to this was added t-butyl amine (5.3 mL) under nitrogen. The reaction mixture was stirred at 40° C. for about 1 hour to crystallize the product. The bis t- butyl amine salt was collected on a Buchner funnel and dried under vacuum to afford 2.21 g of the title compound as an off white crystalline solid.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/757,438 US6362172B2 (en) | 2000-01-20 | 2001-01-10 | Water soluble prodrugs of azole compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17716900P | 2000-01-20 | 2000-01-20 | |
US24996900P | 2000-11-20 | 2000-11-20 | |
US09/757,438 US6362172B2 (en) | 2000-01-20 | 2001-01-10 | Water soluble prodrugs of azole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010041691A1 true US20010041691A1 (en) | 2001-11-15 |
US6362172B2 US6362172B2 (en) | 2002-03-26 |
Family
ID=26873001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/757,438 Expired - Lifetime US6362172B2 (en) | 2000-01-20 | 2001-01-10 | Water soluble prodrugs of azole compounds |
Country Status (22)
Country | Link |
---|---|
US (1) | US6362172B2 (en) |
EP (1) | EP1284737B1 (en) |
JP (1) | JP3766804B2 (en) |
KR (1) | KR100748299B1 (en) |
CN (1) | CN1178665C (en) |
AT (1) | ATE300946T1 (en) |
AU (1) | AU782177C (en) |
BR (1) | BR0107618A (en) |
CA (1) | CA2397734C (en) |
CZ (1) | CZ20022822A3 (en) |
DE (1) | DE60112433T2 (en) |
DK (1) | DK1284737T5 (en) |
ES (1) | ES2247131T3 (en) |
HU (1) | HU229226B1 (en) |
IL (2) | IL150798A0 (en) |
MX (1) | MXPA02007120A (en) |
NO (1) | NO330352B1 (en) |
NZ (1) | NZ519354A (en) |
PL (1) | PL206024B1 (en) |
PT (1) | PT1284737E (en) |
RU (1) | RU2266909C2 (en) |
WO (1) | WO2001052852A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090192316A1 (en) * | 2005-12-20 | 2009-07-30 | Manabu Sasho | Process for preparation of water-soluble azole prodrugs |
US20100249426A1 (en) * | 2006-02-22 | 2010-09-30 | Hayato Ishimoto | Stabilized pharmaceutical composition |
US9981040B2 (en) | 2012-04-20 | 2018-05-29 | Eisai R&D Management Co., Ltd. | Capsule formulation |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
HUP0303249A3 (en) | 2001-02-22 | 2007-03-28 | Sankyo Co | Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1678321A (en) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
PT1856135E (en) | 2005-01-19 | 2010-02-26 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
JO2691B1 (en) | 2005-05-03 | 2013-03-03 | ايساي آر آند دي مانجمنت كو.، ليمتد | Mono-lysine salts of azole compounds |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
EP2043446A2 (en) * | 2006-02-08 | 2009-04-08 | Phibro-Tech Inc. | Biocidal azole emulsion concentrates having high active ingredient content |
PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
AR071175A1 (en) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
AU2009249067A1 (en) * | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Water-soluble acetaminophen analogs |
MX2010012649A (en) | 2008-05-20 | 2010-12-21 | Neurogesx Inc | Carbonate prodrugs and methods of using the same. |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
BRPI0919288A2 (en) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | combination therapy for treatment of diabetes and related conditions. |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN102256976A (en) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | Salt forms of organic compound |
AR074990A1 (en) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY |
KR20210033559A (en) | 2009-11-27 | 2021-03-26 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
CN102946875A (en) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | Combination therapy |
EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US20130288956A1 (en) | 2010-11-05 | 2013-10-31 | Eisai R&D Management Co., Ltd. | Combined pharmaceutical composition as antifungal agent |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
AU2011343576B2 (en) * | 2010-12-16 | 2016-09-08 | Platform Brightworks Two, Ltd. | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
EP2723452A2 (en) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs |
AU2012285904C1 (en) | 2011-07-15 | 2017-08-31 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
KR102061137B1 (en) * | 2012-01-20 | 2019-12-31 | 마이코비아 파마슈티컬즈, 인코포레이티드 | Metalloenzyme Inhibitor Compounds |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US20160128944A1 (en) | 2013-06-04 | 2016-05-12 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
AU2015212312A1 (en) | 2014-01-29 | 2016-08-18 | Vyome Therapeutics Limited | Treatments for resistant acne |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
CN104926870B (en) * | 2014-03-21 | 2017-02-08 | 合肥久诺医药科技有限公司 | Fosfluconazole refining method |
WO2017019875A1 (en) * | 2015-07-28 | 2017-02-02 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compounds prodrugs and their uses |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN107501255B (en) * | 2017-09-12 | 2019-08-23 | 成都施贝康生物医药科技有限公司 | A kind of Chinese mugwort Saperconazole derivative and application thereof |
CN108676031A (en) * | 2018-05-29 | 2018-10-19 | 重庆威鹏药业有限公司 | Water-soluble triazole antifungal phosphinic acid compounds and its preparation method and application |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9308012A (en) | 1992-12-24 | 1994-08-31 | Bristol Myers Squibb Co | PHOSPHONOOXIMETHYL ETHER OF TAXANE DERIVATIVES, SOLUBLE IN WATER AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM. |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5714490A (en) * | 1993-12-21 | 1998-02-03 | Schering Corporation | Tetrahydrofuran antifungals |
ATE204875T1 (en) | 1993-12-21 | 2001-09-15 | Schering Corp | FUNGICIDAL TETRAHYDROFURANES |
PL181947B1 (en) | 1994-01-24 | 2001-10-31 | Janssen Pharmaceutica Nv | Water-soluble azole-type antimycotic agents |
NZ270418A (en) | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
MX9701229A (en) | 1995-06-02 | 1997-05-31 | Schering Corp | Tetrahydrofuran antifungals. |
TW354293B (en) * | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
GB9602080D0 (en) | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
EP0829478A3 (en) | 1996-09-09 | 1998-03-25 | F. Hoffmann-La Roche Ag | N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents |
JP2002501926A (en) | 1998-01-29 | 2002-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | Diaryl 1,3,4-oxadiazolone phosphate derivatives |
US5883097A (en) | 1998-04-16 | 1999-03-16 | Schering Corporation | Soluble azole antifungal salt |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
AU1915500A (en) * | 1998-11-20 | 2000-06-13 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
-
2001
- 2001-01-10 US US09/757,438 patent/US6362172B2/en not_active Expired - Lifetime
- 2001-01-16 WO PCT/US2001/001284 patent/WO2001052852A1/en active IP Right Grant
- 2001-01-16 PT PT01942553T patent/PT1284737E/en unknown
- 2001-01-16 AU AU29485/01A patent/AU782177C/en not_active Expired
- 2001-01-16 MX MXPA02007120A patent/MXPA02007120A/en active IP Right Grant
- 2001-01-16 CZ CZ20022822A patent/CZ20022822A3/en unknown
- 2001-01-16 RU RU2002118606/04A patent/RU2266909C2/en active
- 2001-01-16 EP EP01942553A patent/EP1284737B1/en not_active Expired - Lifetime
- 2001-01-16 CN CNB018038581A patent/CN1178665C/en not_active Expired - Lifetime
- 2001-01-16 NZ NZ519354A patent/NZ519354A/en not_active IP Right Cessation
- 2001-01-16 JP JP2001552899A patent/JP3766804B2/en not_active Expired - Lifetime
- 2001-01-16 DK DK01942553T patent/DK1284737T5/en active
- 2001-01-16 HU HU0204405A patent/HU229226B1/en not_active IP Right Cessation
- 2001-01-16 DE DE60112433T patent/DE60112433T2/en not_active Expired - Lifetime
- 2001-01-16 IL IL15079801A patent/IL150798A0/en active IP Right Grant
- 2001-01-16 AT AT01942553T patent/ATE300946T1/en active
- 2001-01-16 CA CA2397734A patent/CA2397734C/en not_active Expired - Lifetime
- 2001-01-16 KR KR1020027009320A patent/KR100748299B1/en active IP Right Grant
- 2001-01-16 ES ES01942553T patent/ES2247131T3/en not_active Expired - Lifetime
- 2001-01-16 BR BR0107618-3A patent/BR0107618A/en active Search and Examination
- 2001-01-16 PL PL356164A patent/PL206024B1/en not_active IP Right Cessation
-
2002
- 2002-07-17 IL IL150798A patent/IL150798A/en unknown
- 2002-07-19 NO NO20023468A patent/NO330352B1/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090192316A1 (en) * | 2005-12-20 | 2009-07-30 | Manabu Sasho | Process for preparation of water-soluble azole prodrugs |
US7803949B2 (en) | 2005-12-20 | 2010-09-28 | Eisai R&D Management Co., Ltd. | Process for preparation of water-soluble azole prodrugs |
US20100249426A1 (en) * | 2006-02-22 | 2010-09-30 | Hayato Ishimoto | Stabilized pharmaceutical composition |
US9931295B2 (en) | 2006-02-22 | 2018-04-03 | Eisai R&D Management Co., Ltd. | Stabilized pharmaceutical composition |
US9981040B2 (en) | 2012-04-20 | 2018-05-29 | Eisai R&D Management Co., Ltd. | Capsule formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6362172B2 (en) | Water soluble prodrugs of azole compounds | |
US6448401B1 (en) | Process for water soluble azole compounds | |
AU2002213317A1 (en) | Improved process for water soluble azole compounds | |
AU2006241694B2 (en) | Mono-lysine salts of azole compounds | |
US6458961B1 (en) | Water soluble prodrugs of azole compounds | |
ZA200204332B (en) | Water soluble prodrugs of azole compounds. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRISTOL-MEYERS SQUIBB COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UEDA, YASUTSUGU;MATISKELLA, JOHN D.;GOLIK, JERZY;AND OTHERS;REEL/FRAME:011564/0551;SIGNING DATES FROM 20010110 TO 20010115 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: EISAI CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRISTOL-MYERS SQUIBB COMPANY;REEL/FRAME:017586/0317 Effective date: 20051121 |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EISAI CO., LTD.;REEL/FRAME:019640/0618 Effective date: 20070511 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |